Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~2 h
Time for 50 % to be eliminated
Steady State
~9 h
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~14 h
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 9.1 | 4.3 |
| 18.2 | 0.2 |
| 26.542 | 41.4 |
| 35.642 | 1.8 |
| 44.742 | 0.1 |
| 53.083 | 17.2 |
| 62.183 | 0.7 |
| 71.283 | 0 |
| 79.625 | 7.1 |
| 88.725 | 0.3 |
| 97.067 | 69.1 |
| 106.167 | 2.9 |
| 115.267 | 0.1 |
| 123.608 | 28.6 |
| 132.708 | 1.2 |
| 141.808 | 0.1 |
| 150.15 | 11.9 |
| 159.25 | 0.5 |
| 168 | 100 |
| 176.692 | 4.9 |
Source: Pickart et al., plasma pharmacokinetics. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. GHK-Cu: ~2 hours.
GHK-Cu has a reported half-life of about 2 hours. Under a daily dosing schedule, steady state is reached at roughly 4.3 half-lives — about 9 hours — and accumulation is essentially negligible: each daily dose clears almost fully before the next.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 14 hours — seven half-lives.
GHK-Cu is a copper-binding tripeptide studied for skin repair, collagen synthesis, and anti-inflammatory effects. Typical daily doses range from 1 to 4 mg. The very short half-life means each dose is independent, with no meaningful carry-over to the following day.